Luciano Garofano

Luciano Garofano

Auto-generated profile, based on publicly available information

Luciano Garofano

Department of Public Health Sciences, Division of Biostatistics and Bioinformatics, University of Miami, Miller School of Medicine, Miami, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2015 in Nucleic Acids Research
Verified
Journal Article
Open access
ACAntonio Colaprico
Antonio Colaprico
TSTiago Chedraoui Silva
Tiago Chedraoui Silva
COCatharina Olsen
Catharina Olsen
LGLuciano Garofano
Luciano Garofano
CCClaudia Cava
Claudia Cava
HNHoutan Noushmehr
Houtan Noushmehr
The Cancer Genome Atlas (TCGA) research network has made public a large collection of clinical and molecular phenotypes of more than 10 000 tumor patients across 33 different tumor types. Using this cohort, TCGA has published over 20 marker papers detailing the genomic and epigenomic alterations associated with these tumor types. Although many important discoveries have been made by TCGA's research network, opportunities still exist to implement novel methods, thereby elucidating new biological pathways and diagnostic markers. However, mining the TCGA data presents several bioinformatics challenges, such as data retrieval and integration with clinical data and other molecular data types (e.g. RNA and DNA methylation). We developed an R/Bioconductor package called TCGAbiolinks to address these challenges and offer bioinformatics solutions by using a guided workflow to allow users to query, download and perform integrative analyses of TCGA data. We combined methods from computer science and statistics into the pipeline and incorporated methodologies developed in previous TCGA marker studies and in our own group. Using four different TCGA tumor types (Kidney, Brain, Breast and Colon) as examples, we provide case studies to illustrate examples of reproducibility, integrative analysis and utilization of different Bioconductor packages to advance and accelerate novel discoveries.

1 January 2016 in Cell
Verified
Journal Article
Closed access
MCMichele Ceccarelli
Michele Ceccarelli
FBFloris Barthel
Floris Barthel
TMTathiane M. Malta
Tathiane M. Malta
TSThais S. Sabedot
Thais S. Sabedot
SSSofie Reda Salama
Sofie Reda Salama
EZErik Zmuda
Erik Zmuda

11 January 2021 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LGLuciano Garofano
Luciano Garofano
SMSimona Migliozzi
Simona Migliozzi
YOYoung Taek Oh
Young Taek Oh
FDFulvio D'Angelo
Fulvio D'Angelo
RNRyan D. Najac
Ryan D. Najac
AIAntonio Iavarone
Antonio Iavarone

10 December 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
FDFulvio D'Angelo
Fulvio D'Angelo
MCMichele Ceccarelli
Michele Ceccarelli
TATala
Tala
LGLuciano Garofano
Luciano Garofano
JZJing Zhang
Jing Zhang
AIAntonio Iavarone
Antonio Iavarone

3 January 2018 in Nature
Verified
Journal Article
Closed access
PDF file
VFVéronique Frattini
Véronique Frattini
SPStefano Maria Pagnotta
Stefano Maria Pagnotta
TATala
Tala
JFJerry J. Fan
Jerry J. Fan
MRMarco V. Russo
Marco V. Russo
AIAntonio Iavarone
Antonio Iavarone

9 May 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MNMasashi Nomura
Masashi Nomura
ASAvishay Spitzer
Avishay Spitzer
KJKevin C. Johnson
Kevin C. Johnson
LGLuciano Garofano
Luciano Garofano
DNDjamel Nehar-Belaid
Djamel Nehar-Belaid
ITItay Tirosh
Itay Tirosh
In isocitrate dehydrogenase wildtype glioblastoma (GBM), cellular heterogeneity across and within tumors may drive therapeutic resistance. Here we analyzed 121 primary and recurrent GBM samples from 59 patients using single-nucleus RNA sequencing and bulk tumor DNA sequencing to characterize GBM transcriptional heterogeneity. First, GBMs can be classified by their broad cellular composition, encompassing malignant and nonmalignant cell types. Second, in each cell type we describe the diversity of cellular states and their pathway activation, particularly an expanded set of malignant cell states, including glial progenitor cell-like, neuronal-like and cilia-like. Third, the remaining variation between GBMs highlights three baseline gene expression programs. These three layers of heterogeneity are interrelated and partially associated with specific genetic aberrations, thereby defining three stereotypic GBM ecosystems. This work provides an unparalleled view of the multilayered transcriptional architecture of GBM. How this architecture evolves during disease progression is addressed in the companion manuscript by Spitzer et al.